mAb Development

Oct 01, 2016
BioPharm International
An approach to stabilize PBS-based formulations could provide a simple physiological solution for use of proteins in research, preclinical, diagnostics, and clinical studies, as well as commercial biotherapeutic products.
Sep 01, 2016
BioPharm International
This study offers a strategy for stabilization of biotherapeutics for long-term frozen storage in PBS-based formulations.
Sep 01, 2016
BioPharm International
Industry experts discuss best practices for selecting a separation technology.
Sep 01, 2016
BioPharm International
The authors outline cell-line development and process scale-up for an antibody program in which the antibody requires additional processing by a site-specific enzyme for correct functionality.
Aug 15, 2016
By BioPharm International Editors
Jacobs Engineering will provide engineering and construction services to expand the Novartis site in Huningue, France.
Aug 01, 2016
BioPharm International
The study demonstrates a systematic approach to stabilize PBS-formulated mAbs against freeze-thaw degradation.
Jul 28, 2016
By BioPharm International Editors
NIST’s monoclonal antibody reference material can be used as a standard for biopharmaceutical analytical quality control.
Jul 26, 2016
The mAb, in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, was granted a Breakthrough Therapy Designation from FDA for the treatment of multiple myeloma.
Jul 25, 2016
By BioPharm International Editors
The companies filed a BLA for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis.
Jul 05, 2016
By BioPharm International Editors
The acquisition will give Bristol-Myers Squibb full rights to Cormorant’s HuMax-IL8 antibody program.
native1_300x100
lorem ipsum